The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone, but that the benefit was still only a few months for two forms of cancer, study sponsor Neon Therapeutics (NTGN) reported on Monday.

It was a hint that an experimental therapy often described as the next great hope for immune-based approaches to fighting cancer will not be a silver bullet.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • In 2017 I began treating at Mass General Hospital with a series of infusions
    using the immunotherapy drug, Keytruda, to treat melanoma. After 3 series of infusions, beginning in January 2017 and ending in October 2017, the Keytruda had no effect on the melanoma but did destroy my immune system resulting in 3 different hospitalizations in the winter/spring of 2018. I recovered from the non-infectious ulcerative colitis, the pneumonia and SVR infection and the cellulitis. The melanoma was surgically removed in February, 2019. However, I am now disabled as I have been left with Chemo-induced peripheral neuropathy of both my hands and feet, for which there is no cure. . I am no longer independent and need help in my day to day personal care.

    Keytruda basically poisoned me and destroyed my life.

  • You cannot say that adding the vaccine prolongs PFS without a control arm. It is impossible to tell whether there was a benefit to adding the vaccine in this trial – use of the word “longer” leads to the question of longer than what? Longer than seen in a different trial of different patients with probably different doctors, different baseline criteria, different treatment at different centers. Longer than the investigators predicted based on prior data. PFS is a highly variable outcome driven largely by the baseline characteristics of the treated patients and especially fraught when only a small number of patients are included. I would agree, however, that the PFS data are promising and justify more robust studies.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy